Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  




2 External links  













Vesnarinone






●Српски / srpski
 ●Srpskohrvatski / српскохрватски
 ●中文
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  



In other projects  


●Wikimedia Commons
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Vesnarinone
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers

  • 6-[4-(3,4-Dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one

CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H25N3O4
Molar mass395.459 g·mol−1
3D model (JSmol)

  • COC1=C(C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(C=C3)NC(=O)CC4)OC

  • InChI=1S/C22H25N3O4/c1-28-19-7-3-16(14-20(19)29-2)22(27)25-11-9-24(10-12-25)17-5-6-18-15(13-17)4-8-21(26)23-18/h3,5-7,13-14H,4,8-12H2,1-2H3,(H,23,26) ☒N

  • Key:ZVNYJIZDIRKMBF-UHFFFAOYSA-N ☒N

 ☒NcheckY (what is this?)  (verify)

Vesnarinone (INN) is a cardiotonic agent.[1] A mixed phosphodiesterase 3 inhibitor and ion-channel modifier that has modest, dose-dependent, positive inotropic activity, but minimal negative chronotropic activity. Vesnarinone improves ventricular performance most in patients with the worst degree of heart failure.

References

[edit]
  1. ^ Cavusoglu E, Frishman WH, Klapholz M (June 1995). "Vesnarinone: a new inotropic agent for treating congestive heart failure". Journal of Cardiac Failure. 1 (3): 249–257. doi:10.1016/1071-9164(95)90030-6. PMID 9420657.
[edit]
Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Vesnarinone&oldid=1134910955"
    Categories: 
    ●Drugs not assigned an ATC code
     ●N-benzoylpiperazines
     ●Inotropic agents
     ●PDE3 inhibitors
     ●Catechol ethers
     ●Phenylpiperazines
     ●2-Quinolones
     ●Cardiovascular system drug stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Drugs with non-standard legal status
     ●Articles with changed ChemSpider identifier
     ●Articles with changed EBI identifier
     ●Articles with changed InChI identifier
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Drugboxes which contain changes to verified fields
     ●Drugboxes which contain changes to watched fields
     ●Commons category link from Wikidata
     ●All stub articles
      


    ●This page was last edited on 21 January 2023, at 12:06 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki